论文部分内容阅读
目的对比观察单药多西他赛每周方案与每3周方案二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效?毒副反应及生活质量。方法每周方案组(A组):多西他赛35 mg/m2,静滴,第1、8、15天,每4周重复;三周方案组(B组):多西他赛75 mg/m2,静滴,第1天,每3~4周重复,治疗2个周期评价疗效,每周期评价毒性。采用欧洲癌症研究和治疗组织(EORTC)简体中文版的生活质量调查核心问卷(QLQ-C30)和肺癌专用问卷(QLQ-LC13)评价患者生活质量,化疗前及治疗2个周期后给予评价生活质量。结果A组32例,B组35例,67例均无完全缓解(CR);部分缓解(PR):A组3例,B组4例;稳定(SD)A组5例,B组6例;有效率(RR):A组9.4%,B组11.4%(P=1.000);临床获益率:A组25.0%,B组28.6%(P=0.742)。中位生存期:A组9.2个月,B组6.3个月(P=0.07)。1年生存率:A组31.3%,B组28.6%(P=0.811)。两组Ⅲ/Ⅳ度粒细胞减少分别为15.6%和48.6%(P=0.004)。化疗后两组患者在气促?咳嗽?咯血?疼痛方面症状明显减轻,A组与B组比较,在疼痛(P=0.040)、咳嗽(P=0.045)两方面分值降低明显,差异有显著性。结论单药多西他赛二线治疗晚期非小细胞肺癌,每周方案与三周方案有效率相似,每周方案血液学毒性明显下降,临床症状明显改善,耐受性更好。
Objective To compare and observe the clinical curative effect of single-dose docetaxel weekly and third-line second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) .Toxicity and quality of life. Methods Weekly program group (group A): docetaxel 35 mg / m2, intravenous drip, days 1,8,15 repeated every 4 weeks; three weeks program group (group B): docetaxel 75 mg / m2, intravenous drip, on the first day, repeated every 3 to 4 weeks, 2 cycles of treatment evaluation of efficacy, toxicity was evaluated every cycle. Quality of life was assessed using the QLQ-C30 and QLQ-LC13 versions of the Simplified Chinese version of the European Organization for Research and Treatment of Cancer (EORTC). Quality of life was assessed before chemotherapy and after 2 cycles of treatment . Results There were 32 cases in group A, 35 cases in group B, and 67 cases in group B. There were 3 cases in group A and 4 cases in group B, 5 cases in group A, 5 cases in group A, 6 cases in group B The effective rate (RR) was 9.4% in group A and 11.4% in group B (P = 1.000). The clinical benefit rate was 25.0% in group A and 28.6% in group B (P = 0.742). Median survival was 9.2 months in group A and 6.3 months in group B (P = 0.07). The 1-year survival rate was 31.3% in group A and 28.6% in group B (P = 0.811). The III / IV neutropenia in both groups was 15.6% and 48.6%, respectively (P = 0.004). After chemotherapy, the symptoms of both groups were obviously relieved in patients with shortness of breath, cough, and hemoptysis. There was significant difference between the two groups in pain (P = 0.040) and cough (P = 0.045) in group A and group B Sex. Conclusion The second-line single-agent docetaxel treatment of advanced non-small cell lung cancer, the weekly program and the three-week program is similar to the efficiency of the weekly program significantly decreased hematological toxicity, clinical symptoms improved significantly better tolerated.